The antiretroviral protease inhibitors indinavir and nelfinavir stimulate Mrp1-mediated GSH export from cultured brain astrocytes

Journal of Neurochemistry

Volumn 120, Issue 1, 2012, Pages 78-92

  Brandmann, Maria ^a   Tulpule, Ketki ^a   Schmidt, Maike M ^a   Dringen, Ralf ^a  

^a UNIVERSITY OF BREMEN   (Germany)

Author keywords

AIDS; glutathione; HIV; multidrug resistance protein; transport

Indexed keywords

EFAVIRENZ; GLUTATHIONE; GLUTATHIONE DISULFIDE; HYDROGEN PEROXIDE; INDINAVIR; LACTATE DEHYDROGENASE; LAMIVUDINE; MULTIDRUG RESISTANCE PROTEIN 1; NELFINAVIR; NEVIRAPINE; REACTIVE OXYGEN METABOLITE; VERLUKAST; ZIDOVUDINE;

ANIMAL CELL; ARTICLE; ASTROCYTE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; GLUTATHIONE METABOLISM; NEUROTOXICITY; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ANIMALS; ANIMALS, NEWBORN; ASTROCYTES; BRAIN CHEMISTRY; CELL SURVIVAL; CELLS, CULTURED; GLUCOSE; GLUTATHIONE; HIV PROTEASE INHIBITORS; HYDROGEN PEROXIDE; INDINAVIR; LACTIC ACID; LEUKOTRIENE ANTAGONISTS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NELFINAVIR; OXIDATIVE STRESS; PROPIONATES; QUINOLINES; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 83855162737     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2011.07544.x     Document Type: Article

References (102)

1. Anderson B. D., May M. J., Jordan S., Song L., Roberts M. J., and, Leggas M., (2006) Dependence of nelfinavir brain uptake on dose and tissue concentrations of the selective P-glycoprotein inhibitor zosuquidar in rats. Drug Metab. Dispos. 34, 653-659.
2. Aoyama K., Watabe M., and, Nakaki T., (2008) Regulation of neuronal glutathione synthesis. J. Pharmacol. Sci. 108, 227-238.
3. Bachmeier C. J., Spitzenberger T. J., Elmquist W. F., and, Miller D. W., (2005) Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm. Res. 22, 1259-1268. (Pubitemid 41176029)
4. Baede-van Dijk P. A., Hugen P. W., Verweij-van Wissen C. P., Koopmans P. P., Burger D. M., and, Hekster Y. A., (2001) Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS 15, 991-998. (Pubitemid 32476666)
5. Barros L. F., and, Deitmer J. W., (2010) Glucose and lactate supply to the synapse. Brain Res. Rev. 63, 149-159.
6. Bateman K. P., Castro-Perez J., Wrona M., Shockcor J. P., Yu K., Oballa R., and, Nicoll-Griffith D. A., (2007) MSE with mass defect filtering for in vitro and in vivo metabolite identification. Rapid Commun. Mass Spectrom. 21, 1485-1496. (Pubitemid 46761970)
7. Bazzoli C., Jullien V., Le Tiec C., Rey E., Mentre F., and, Taburet A. M., (2010) Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin. Pharmacokinet. 49, 17-45.
8. Ben-Romano R., Rudich A., Etzion S., Potashnik R., Kagan E., Greenbaum U., and, Bashan N., (2006) Nelfinavir induces adipocyte insulin resistance through the induction of oxidative stress: differential protective effect of antioxidant agents. Antivir. Ther. 11, 1051-1060. (Pubitemid 44955181)
9. Bierman W. F., van Agtmael M. A., Nijhuis M., Danner S. A., and, Boucher C. A., (2009) HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 23, 279-291.
10. Bishop G. M., Dringen R., and, Robinson S. R., (2007) Zinc stimulates the production of toxic reactive oxygen species (ROS) and inhibits glutathione reductase in astrocytes. Free Radic. Biol. Med. 42, 1222-1230. (Pubitemid 46428515)
11. Brechbuhl H. M., Gould N., Kachadourian R., Riekhof W. R., Voelker D. R., and, Day B. J., (2010) Glutathione transport is a unique function of the ATP-binding cassette protein ABCG2. J. Biol. Chem. 285, 16582-16587.
12. Burger D. M., Hugen P. W., Aarnoutse R. E., et al. (2001) A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy. J. Acquir. Immune Defic. Syndr. 26, 218-224. (Pubitemid 32246551)
13. Byrd A. S., Sikorska M., Walker P. R., and, Sandhu J. K., (2004) Effects of glutathione depletion on the viability of human NT2-derived neuronal and astroglial cultures. Neuron Glia Biol. 1, 317-326.
14. Chandler B., Almond L., Ford J., Owen A., Hoggard P., Khoo S., and, Back D., (2003) The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro. J. Acquir. Immune Defic. Syndr. 33, 551-556. (Pubitemid 36975841)
15. Chiba M., Hensleigh M., and, Lin J. H., (1997) Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. Biochem. Pharmacol. 53, 1187-1195. (Pubitemid 27224265)
16. Choo E. F., Leake B., Wandel C., Imamura H., Wood A. J., Wilkinson G. R., and, Kim R. B., (2000) Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos. 28, 655-660. (Pubitemid 30390404)
17. Chow W. A., Jianf C., and, Guan M., (2009) Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol. 10, 61-71.
18. Churchill M. J., Wesselingh S. L., Cowley D., Pardo C. A., McArthur J. C., Brew B. J., and, Gorry P. R., (2009) Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann. Neurol. 66, 253-258.
19. Decleves X., Regina A., Laplanche J. L., Roux F., Boval B., Launay J. M., and, Scherrmann J. M., (2000) Functional expression of P-glycoprotein and multidrug resistance-associated protein (Mrp1) in primary cultures of rat astrocytes. J. Neurosci. Res. 60, 594-601. (Pubitemid 30368275)
20. Dixit V., Hariparsad N., Li F., Desai P., Thummel K. E., and, Unadkat J. D., (2007) Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab. Dispos. 35, 1853-1859. (Pubitemid 47481578)
21. Dringen R., (2009) Neuron-glia coupling in glutathione metabolism, in The new Encyclopedia of Neuroscience (, Squire L., Albright T., Bloom F., Gage F., and, Spitzer N., eds), pp. 733-737. Elsevier, Oxford.
22. Dringen R., and, Hamprecht B., (1996) Glutathione content as an indicator for the presence of metabolic pathways of amino acids in astroglial cultures. J. Neurochem. 67, 1375-1382. (Pubitemid 26314191)
23. Dringen R., and, Hamprecht B., (1997) Involvement of glutathione peroxidase and catalase in the disposal of exogenous hydrogen peroxide by cultured astroglial cells. Brain Res. 759, 67-75. (Pubitemid 27286345)
24. Dringen R., Gebhardt R., and, Hamprecht B., (1993) Glycogen in astrocytes: possible function as lactate supply for neighboring cells. Brain Res. 623, 208-214. (Pubitemid 23275402)
25. Dringen R., Kranich O., and, Hamprecht B., (1997) The γ-glutamyl transpeptidase inhibitor acivicin preserves glutathione released by astroglial cells in culture. Neurochem. Res. 22, 727-733. (Pubitemid 27242249)
26. Dringen R., Kussmaul L., and, Hamprecht B., (1998) Detoxification of exogenous hydrogen peroxide and organic hydroperoxides by cultured astroglial cells assessed by microtiter plate assay. Brain Res. Protoc. 2, 223-228. (Pubitemid 28277484)
27. Dringen R., Pawlowski P. G., and, Hirrlinger J., (2005) Peroxide detoxification by brain cells. J. Neurosci. Res. 79, 157-165. (Pubitemid 40116430)
28. Drukarch B., Schepens E., Jongenelen C. A., Stoof J. C., and, Langeveld C. H., (1997) Astrocyte-mediated enhancement of neuronal survival is abolished by glutathione deficiency. Brain Res. 770, 123-130. (Pubitemid 27468059)
29. Durant J., Clevenbergh P., Garraffo R., Halfon P., Icard S., Del Giudice P., Montagne N., Schapiro J. M., and, Dellamonica P., (2000) Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 14, 1333-1339. (Pubitemid 30459505)
30. Eulenburg V., and, Gomeza J., (2010) Neurotransmitter transporters expressed in glial cells as regulators of synapse function. Brain Res. Rev. 63, 103-112.
31. Ford J., Khoo S. H., and, Back D. J., (2004) The intracellular pharmacology of antiretroviral protease inhibitors. J. Antimicrob. Chemother. 54, 982-990. (Pubitemid 40136729)
32. Garden G. A., (2002) Microglia in human immunodeficiency virus-associated neurodegeneration. Glia 40, 240-251. (Pubitemid 35337381)
33. Gegg M. E., Clark J. B., and, Heales S. J., (2005) Co-culture of neurones with glutathione deficient astrocytes leads to increased neuronal susceptibility to nitric oxide and increased glutamate-cysteine ligase activity. Brain Res. 1036, 1-6. (Pubitemid 40255838)
34. Ghafouri M., Amini S., Khalili K., and, Sawaya B. E., (2006) HIV-1 associated dementia: symptoms and causes. Retrovirology 3, 28.
35. Ghosh C., Puvenna V., Gonzalez-Martinez J., Janigro D., and, Marchi N., (2011) Blood-brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases. Curr. Drug Metab. [Epub ahead of print].
36. Gills J. J., Lopiccolo J., Tsurutani J., et al. (2007) Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin. Cancer Res. 13, 5183-5194. (Pubitemid 47502088)
37. Gimenez F., Fernandez C., and, Mabondzo A., (2004) Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins. J. Acquir. Immune Defic. Syndr. 36, 649-658. (Pubitemid 38685958)
38. Glynn S. L., and, Yazdanian M., (1998) In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J. Pharm. Sci. 87, 306-310. (Pubitemid 28204583)
39. Hamprecht B., and, Löffler F., (1985) Primary glial cultures as a model for studying hormone action. Methods Enzymol. 109, 341-345. (Pubitemid 15136041)
40. Hazleton J. E., Berman J. W., and, Eugenin E. A., (2010) Novel mechanisms of central nervous system damage in HIV infection. HIV AIDS Res. Palliat. Care 2, 39-49.
41. Hirani V. N., Raucy J. L., and, Lasker J. M., (2004) Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab. Dispos. 32, 1462-1467. (Pubitemid 39564567)
42. Hirrlinger J., and, Dringen R., (2010) The cytosolic redox state of astrocytes: maintenance, regulation and functional implications for metabolite trafficking. Brain Res. Rev. 63, 177-188.
43. Hirrlinger J., Hamprecht B., and, Dringen R., (1999) Application and modulation of a permanent hydrogen peroxide-induced oxidative stress to cultured astroglial cells. Brain Res. Protoc. 4, 223-229. (Pubitemid 29396423)
44. Hirrlinger J., König J., Keppler D., Lindenau J., Schulz J. B., and, Dringen R., (2001) The multidrug resistance protein MRP1 mediates the release of glutathione disulfide from rat astrocytes during oxidative stress. J. Neurochem. 76, 627-636. (Pubitemid 32097039)
45. Hirrlinger J., König J., and, Dringen R., (2002a) Expression of mRNAs of multidrug resistance proteins (Mrps) in cultured rat astrocytes, oligodendrocytes, microglial cells and neurones. J. Neurochem. 82, 716-719. (Pubitemid 34831509)
46. Hirrlinger J., Schulz J. B., and, Dringen R., (2002b) Glutathione release from cultured brain cells: multidrug resistance protein 1 mediates the release of GSH from rat astroglial cells. J. Neurosci. Res. 69, 318-326. (Pubitemid 34809481)
47. Hoepken H. H., Korten T., Robinson S. R., and, Dringen R., (2004) Iron accumulation, iron-mediated toxicity and altered levels of ferritin and transferrin receptor in cultured astrocytes during incubation with ferric ammonium citrate. J. Neurochem. 88, 1194-1202. (Pubitemid 38280687)
48. Hoggard P. G., and, Owen A., (2003) The mechanisms that control intracellular penetration of the HIV protease inhibitors. J. Antimicrob. Chemother. 51, 493-496. (Pubitemid 36336141)
49. Huang L., Wring S. A., Woolley J. L., Brouwer K. R., Serabjit-Singh C., and, Polli J. W., (2001) Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab. Dispos. 29, 754-760. (Pubitemid 32374579)
50. Hugen P. W., Verweij-van Wissen C. P., Burger D. M., Wuis E. W., Koopmans P. P., and, Hekster Y. A., (1999) Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 727, 139-149. (Pubitemid 29189286)
51. Jamaluddin M. S., Lin P. H., Yao Q., and, Chen C., (2010) Non-nucleoside reverse transcriptase inhibitor efavirenz increases monolayer permeability of human coronary artery endothelial cells. Atherosclerosis 208, 104-111.
52. Janáky R., Cruz-Aguado R., Oja S. S., and, Shaw C. A., (2007) Glutathione in the nervous system: roles in neural function and health and implications for neurological disease, in Handbook of Neurochemistry (, Oja S. S., Shousboe A., and, Saransaari P., eds), Vol. Amino Acids and Peptides in the Nervous System, pp. 347-399. Springer, Heidelberg.
53. Jiang B., Hebert V. Y., Li Y., Mathis J. M., Alexander J. S., and, Dugas T. R., (2007) HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis. Toxicol. Appl. Pharmacol. 224, 60-71. (Pubitemid 47404622)
54. Kaddoumi A., Choi S. U., Kinman L., Whittington D., Tsai C. C., Ho R. J. Y., Anderson B. D., and, Unadkat J. D., (2007) Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid. Drug Metab. Dispos. 35, 1459-1462. (Pubitemid 47296072)
55. Kim R. B., Fromm M. F., Wandel C., Leake B., Wood A. J., Roden D. M., and, Wilkinson G. R., (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101, 289-294. (Pubitemid 28067324)
56. Klabe R. M., Bacheler L. T., Ala P. J., Erickson-Viitanen S., and, Meek J. L., (1998) Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency. Biochemistry 37, 8735-8742. (Pubitemid 28299611)
57. Koopmans P. P., Ellis R., Best B. M., and, Letendre S., (2009) Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration? Neth. J. Med. 67, 206-211.
58. Koudriakova T., Iatsimirskaia E., Utkin I., Gangl E., Vouros P., Storozhuk E., Orza D., Marinina J., and, Gerber N., (1998) Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab. Dispos. 26, 552-561. (Pubitemid 28498361)
59. Kruh G. D., and, Belinsky M. G., (2003) The MRP family of drug efflux pumps. Oncogene 22, 7537-7552. (Pubitemid 37487175)
60. Lagathu C., Eustace B., Prot M., et al. (2007) Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir. Ther. 12, 489-500. (Pubitemid 47041147)
61. Lee C. G., Gottesman M. M., Cardarelli C. O., Ramachandra M., Jeang K. T., Ambudkar S. V., Pastan I., and, Dey S., (1998) HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37, 3594-3601. (Pubitemid 28162914)
62. Leslie E. M., Deeley R. G., and, Cole S. P., (2003) Bioflavonoid stimulation of glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). Drug Metab. Dispos. 31, 11-15. (Pubitemid 36735252)
63. Liddell J. R., Dringen R., Crack P. J., and, Robinson S. R., (2006a) Glutathione peroxidase 1 and a high cellular glutathione concentration are essential for effective organic hydroperoxide detoxification in astrocytes. Glia 54, 873-879. (Pubitemid 44671992)
64. Liddell J. R., Hoepken H. H., Crack P. J., Robinson S. R., and, Dringen R., (2006b) Glutathione peroxidase 1 and glutathione are required to protect mouse astrocytes from iron-mediated hydrogen peroxide toxicity. J. Neurosci. Res. 84, 578-586. (Pubitemid 44196698)
65. Liddell J. R., Zwingmann C., Schmidt M. M., Thiessen A., Leibfritz D., Robinson S. R., and, Dringen R., (2009) Sustained hydrogen peroxide stress decreases lactate production by cultured astrocytes. J. Neurosci. Res. 87, 2696-2708.
66. Lindl K. A., Marks D. R., Kolson D. L., and, Jordan-Sciutto K. L., (2010) HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J. Neuroimmune Pharmacol. 5, 294-309.
67. Liner K. J. 2nd, Ro M. J., and, Robertson K. R., (2010) HIV, antiretroviral therapies, and the brain. Curr. HIV/AIDS Rep. 7, 85-91.
68. Loe D. W., Deeley R. G., and, Cole S. P., (2000) Verapamil stimulates glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). J. Pharmacol. Exp. Ther. 293, 530-538. (Pubitemid 30244104)
69. Lowry O. H., Rosebrough N. J., Farr A. L., and, Randall R. J., (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
70. Malaplate-Armand C., Leininger-Muller B., and, Batt A. M., (2004) [Astrocytic cytochromes P450: an enzyme subfamily critical for brain metabolism and neuroprotection]. Rev. Neurol. (Paris) 160, 651-658. (Pubitemid 39044687)
71. Marra C. M., Zhao Y., Clifford D. B., et al. (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23, 1359-1366.
72. Meyer R. P., Gehlhaus M., Knoth R., and, Volk B., (2007) Expression and function of cytochrome P450 in brain drug metabolism. Curr. Drug Metab. 8, 297-306. (Pubitemid 46780059)
73. Miksys S., and, Tyndale R. F., (2004) The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metab. Rev. 36, 313-333. (Pubitemid 38802491)
74. Minich T., Riemer J., Schulz J. B., Wielinga P., Wijnholds J., and, Dringen R., (2006) The multidrug resistance protein 1 (Mrp1), but not Mrp5, mediates export of glutathione and glutathione disulfide from brain astrocytes. J. Neurochem. 97, 373-384.
75. Minuesa G., Huber-Ruano I., Pastor-Anglada M., Koepsell H., Clotet B., and, Martinez-Picado J., (2011) Drug uptake transporters in antiretroviral therapy. Pharmacol. Ther. 132, 268-279.
76. Mondal D., Pradhan L., Ali M., and, Agrawal K. C., (2004) HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants. Cardiovasc. Toxicol. 4, 287-302. (Pubitemid 39382991)
77. Olson D. P., Scadden D. T., D'Aquila R. T., and, De Pasquale M. P., (2002) The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS 16, 1743-1747.
78. Palmeira V. F., Kneipp L. F., Rozental S., Alviano C. S., and, Santos A. L., (2008) Beneficial effects of HIV peptidase inhibitors on Fonsecaea pedrosoi: promising compounds to arrest key fungal biological processes and virulence. PLoS ONE 3, e3382.
79. Perea G., and, Araque A., (2010) GLIA modulates synaptic transmission. Brain Res. Rev. 63, 93-102.
80. Pfrieger F. W., (2010) Role of glial cells in the formation and maintenance of synapses. Brain Res. Rev. 63, 39-46.
81. Rappa G., Lorico A., Flavell R. A., and, Sartorelli A. C., (1997) Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural produce toxins. Cancer Res. 57, 5232-5237. (Pubitemid 27516354)
82. Robertson K. R., Smurzynski M., Parsons T. D., et al. (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21, 1915-1921. (Pubitemid 47329768)
83. Robey R. W., Massey P. R., Amiri-Kordestani L., and, Bates S. E., (2010) ABC transporters: unvalidated therapeutic targets in cancer and the CNS. Anticancer Agents Med. Chem. 10, 625-633.
84. Sagara J., Makino N., and, Bannai S., (1996) Glutathione efflux from cultured astrocytes. J. Neurochem. 66, 1876-1881. (Pubitemid 26118775)
85. Sakaeda T., Nakamura T., and, Okumura K., (2002) MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol. Pharm. Bull. 25, 1391-1400. (Pubitemid 39663152)
86. van der Sandt I. C., Vos C. M., Nabulsi L., Blom-Roosemalen M. C., Voorwinden H. H., de Boer A. G., and, Breimer D. D., (2001) Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS 15, 483-491. (Pubitemid 32207568)
87. Scheiber I. F., and, Dringen R., (2011) Copper-treatment increases the cellular GSH content and accelerates GSH export from cultured rat astrocytes. Neurosci. Lett. 498, 42-46.
88. Scheiber I. F., Schmidt M. M., and, Dringen R., (2010) Zinc prevents the copper-induced damage of cultured astrocytes. Neurochem. Int. 57, 314-322.
89. Schmidt M. M., and, Dringen R., (2009) Differential effects of iodoacetamide and iodoacetate on glycolysis and glutathione metabolism of cultured astrocytes. Front. Neuroenergetics 1, 1-10.
90. Schmidt M. M., and, Dringen R., (2010) Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione. Neurochem. Int. 57, 460-467.
91. Schmidt M. M., and, Dringen R., (2012) GSH synthesis and metabolism, in: Advances in Neurobiology (, Gruetter R., and, Choi I. Y., eds), Vol. Neural Metabolism in Vivo. Springer, New York, in press.
92. Schmidt M. M., Rohwedder A., and, Dringen R., (2011) Effects of chlorinated acetates on the glutathione metabolism and on glycolysis of cultured astrocytes. Neurotox. Res. 19, 628-637.
93. Sofroniew M. V., and, Vinters H. V., (2010) Astrocytes: biology and pathology. Acta Neuropathol. 119, 7-35.
94. Solas C., Lafeuillade A., Halfon P., Chadapaud S., Hittinger G., and, Lacarelle B., (2003) Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47, 238-243. (Pubitemid 36070370)
95. Steele M. L., and, Robinson S. R., (2010) Reactive astrocytes give neurons less support: implications for Alzheimer's disease. Neurobiol. Aging Published Online doi:10.1016/j.neurobiolaging.2010.09.018.
96. Toyoda Y., Hagiya Y., Adachi T., Hoshijima K., Kuo M. T., and, Ishikawa T., (2008) MRP class of human ATP binding cassette (ABC) transporters: historical background and new research directions. Xenobiotica 38, 833-862.
97. Tozzi V., Balestra P., Bellagamba R., et al. (2007) Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J. Acquir. Immune Defic. Syndr. 45, 174-182. (Pubitemid 46869810)
98. Tulpule K., and, Dringen R., (2011) Formaldehyde stimulates Mrp1-mediated glutathione deprivation of cultured astrocytes. J. Neurochem. 116, 626-635.
99. Wang X., Chai H., Lin P. H., Yao Q., and, Chen C., (2009) Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells. Am. J. Pathol. 174, 771-781.
100. Williams G. C., and, Sinko P. J., (1999) Oral absorption of the HIV protease inhibitors: a current update. Adv. Drug Deliv. Rev. 39, 211-238. (Pubitemid 29430237)
101. Wong H. L., Chattopadhyay N., Wu X. Y., and, Bendayan R., (2010) Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv. Drug Deliv. Rev. 62, 503-517.
102. Zhang K. E., Wu E., Patick A. K., et al. (2001) Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob. Agents Chemother. 45, 1086-1093. (Pubitemid 32230986)